Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients

Immune-related adverse events (irAEs) have been described with immune checkpoint inhibitors (ICIs), but the incidence and relative risk (RR) of irAEs associated with these drugs remains unclear. We selected five key irAEs from treatments with approved cytotoxic T-lymphocyte–associated protein 4 (CTL...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Immunol Res
Main Authors: de Velasco, Guillermo, Je, Youjin, Bossé, Dominick, Awad, Mark M., Ott, Patrick A., Moreira, Raphael B., Schutz, Fabio, Bellmunt, Joaquim, Sonpavde, Guru P., Hodi, F. Stephen, Choueiri, Toni K.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5418853/
https://ncbi.nlm.nih.gov/pubmed/28246107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0237
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki